Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall
survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A …

Importance Previous communication has reported significant improvement in overall survival
(OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular …

4003 Background: An exploratory analysis of a randomized phase II study in HCC
comparing doxorubicin (D) alone to doxorubicin plus sorafenib (D+ S) showed a significant …

Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular
carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid …

Purpose Sorafenib improves overall survival and time to progression of advanced
hepatocellular (aHCC) patients such as demonstrated in 2 phase III trials. However, aHCC …

Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

Background No effective systemic therapy exists for patients with advanced hepatocellular
carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the …

Hepatocellular carcinoma (HCC) is the fifth most common cancer and it is the third leading
cause of cancer-related deaths worldwide. Once diagnosed with the disease, only 30-40 …

There is no effective systemic therapy for patients with advanced hepatocellular carcinoma
(HCC) except liver transplantation. Sorafenib, a multikinase inhibitor, has been shown to …

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment
Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival …